Instruction for use: Pirenzepine (Pirenzepinum)

chemical name

5,11-Dihydro-11 - [(4-methyl-1-piperazinyl) -acetyl] -6H- pyrido [2,3-b] [1,4] benzodiazepin-6-one (as dihydrochloride)

Pharmacological group

M Cholinolytics

The nosological classification (ICD-10)

K21.0 Gastro-oesophageal reflux with oesophagitis

Reflux gastritis, Reflux esophagitis, Erosive and ulcerative esophagitis

K22.1 Ulcer of esophagus

Erosion of the mucosa of the upper gastrointestinal tract

K25 Gastric ulcer

Helicobacter pylori, Pain syndrome in gastric ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, Inflammation of the gastric mucosa, Inflammation of the gastrointestinal mucosa, Benign gastric ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Aggravation gastroduodenita on the background of peptic ulcer, Exacerbation of peptic ulcer, The aggravation of gastric ulcer, The organic gastrointestinal disease, Peptic ulcer of the stomach and duodenum, Postoperative gastric ulcer, Recurrent ulcers, Symptomatic gastric ulcers, Chronic inflammatory disease of the upper gastrointestinal tract, associated with Helicobacter pylori, Helicobacter pylori eradication, Erosive and ulcerative lesions of the stomach, Erosive lesions of the stomach, The erosion of the gastric mucosa, Peptic ulcer disease, Stomach ulcer, Gastric lesion, Ulcerative lesions of the stomach, Symptomatic ulcers of the stomach and duodenum

K26 Duodenal Ulcer

Pain with duodenal ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Exacerbation of peptic ulcer, The worsening of duodenal ulcer, Peptic ulcer of the stomach and duodenum, Relapse of duodenal ulcers, Symptomatic ulcers of the stomach and duodenum, Helicobacter pylori eradication, Erosive and ulcerative lesions of the duodenum, Erosive-ulcerative lesions of duodenal ulcers associated with Helicobacter pylori, Erosive lesions of the duodenum, Duodenal ulcer, Ulcerative lesions of the duodenum]

K27 Peptic ulcer, unspecified

Perforation of peptic ulcer, Drug-induced gastrointestinal ulcers, medication ulcers, Peptic ulcer of the digestive tract, Peptic ulcer with Helicobacter pylori, peptic ulcer, Damage of gastrointestinal mucosa caused by NSAID, Symptomatic ulcers digestive tract, stress ulcer, Stress gastric ulcer, Stress damage to the mucous membrane, stress ulcer, duodenal ulcer Stress, Stress ulcer, Stressful GI ulcers, Erosive-ulcerative lesions of the gastrointestinal tract, The erosion of the gastrointestinal tract, Erosion of the mucosa of the upper gastrointestinal tract, The erosion of the gastrointestinal mucosa, gastrointestinal ulcer, ulcer drug, peptic ulcer, postoperative ulcer, stress ulcer, Ulcerative lesions of the gastrointestinal tract, Acute stress ulcer gastrointestinal tract, Symptomatic gastrointestinal ulcers, Complications of peptic ulcers

K86.8.3 * Zollinger-Ellison Syndrome

Adenoma of the pancreas ulzerogennosti, gastrinoma, Zollinger-Ellison Syndrome, gastrinoma

K92.2 Gastro-intestinal bleeding, unspecified

Gastric and intestinal bleeding, Acute bleeding from the upper gastrointestinal tract, gastrorrhagia, Gastrointestinal bleeding, Intraoperative abdominal bleeding, enterorrhagia, Bleeding in the upper digestive tract, Gastrointestinal bleeding, Bleeding from the upper gastrointestinal tract, Bleeding from the gastrointestinal tract, Intraoperative bleeding abdominal, Recurrent bleeding in the digestive tract, Diagnosis of bleeding from the small intestine, peptic ulcer bleeding, Mallory-Weiss syndrome, Recurrent bleeding from peptic ulcers, Bleeding stomach

Y45 adverse reactions in therapeutic use of analgesic, antipyretic and anti-inflammatory agents

Y45.4 Adverse effects in therapeutic use antirheumatic agents

Code CAS 28797-61-7

Pharmacology

Mode of action - antiulcer, gastroprotective.

Selectively blocking cholinergic receptors M1-level intramural ganglia and off the vagus nerve stimulating effect on gastric secretion. Cytoprotective effects associated with improved microcirculation in gastric mucosa and suppression of intragastric proteolysis.

In the digestive tract sucked 1 / 2-1 / 3 doses. Cmax in the plasma generated in 3-4 hours. Approximately 10% bound to plasma proteins. Through the BBB and placenta does not pass. It is metabolized to a minor extent. The decline in plasma by 50% occurs through 8-20 hours. The suck of the drug excreted by the kidneys and bile in unchanged form.

Selectively inhibits both basal and stimulated acid secretion of pepsinogen and reduces the overall activity of gastric juice. Reduces the release of gastrin in response to food stimulation, increases the resistance of gastric mucosal cell damage. When it is advisable to hypersecretion combined with blockers of histamine H2-receptor and antacids. At the beginning of treatment is recommended to combine oral and parenteral administration, one dose is administered i / m, the other - taken orally. In severe forms of gastric ulcer and duodenal ulcer, for the treatment and prevention of bleeding, erosions and ulcerations appointed by the / m or / in. After improvement (after 2-3 days), move on to oral.

Indication

Gastric ulcer and duodenal ulcers (treatment and prevention); hyperacid chronic reflux esophagitis; erosive and ulcerative lesions of the gastrointestinal tract, including caused by anti-rheumatic and anti-inflammatory drugs; stress ulcer gastrointestinal tract; Zollinger-Ellison syndrome; bleeding from erosions and ulcerations in the upper gastrointestinal tract.

Contraindications

Hypersensitivity.

Restrictions apply

Glaucoma, prostatic hyperplasia, tachycardia.

Side effects

Dry mouth, paresis of accommodation, diarrhea, allergic reactions.

Routes of administration

Inside, in / m, / in.

Precautions

With the rapid subjective improvement should not stop taking it because of the possible deterioration of the state. The on / in the introduction is necessary to monitor the state of the cardiovascular system.